A Bio‐Liposome Activating Natural Killer Cell by Illuminating Tumor Homogenization Antigen Properties

Abstract

AbstractNatural killer (NK) cell therapies, primarily based on chimeric antigen receptor NK cells (CAR‐NK), have been developed and applied clinically for therapeutic treatment of patients with mid‐to‐late‐stage tumors. However, NK cell therapy has limited efficacy due to insufficient antigen expression on the tumor cell surface. Here, a universal “illuminate tumor homogenization antigen properties” (ITHAP) strategy to achieve stable and controlled antigen expression on the surface of tumor cells using nanomedicine, thus significantly enhancing the immune recognizability of tumor cells, is described. The ITHAP strategy is used to generate bio‐liposomes (Pt@PL‐IgG) composed of intermingled platelet membranes and liposomes with NK‐activatable target antigen (IgG antibodies) and cisplatin pre‐drug. It is demonstrated that Pt@PL‐IgG successfully targets tumor cells using the autonomous drive of platelet membranes and achieves IgG implantation on tumor cells by utilizing membrane fusion properties. Moreover, it is shown that the Pt‐DNA complex combined with NK cell‐induced pyroptosis causes substantial interferon (IFN) secretion, thus providing a synthase‐stimulator of interferon genes (STING)‐IFN‐mediated positive immune microenvironment to further potentiate NK therapy. These results show that anchoring cancer cells with NK‐activatable target antigens is a promising translational strategy for addressing therapeutic challenges in tumor heterogeneity.